You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Pfizer donates USD 70 mn worth Covid-19 treatment drugs to India

Global pharma major Pfizer is sending its medicines worth USD 70 million from its distribution centres in the US, Europe and Asia

Pfizer | Coronavirus | drugs

Press Trust of India  |  New Delhi 

Pfizer vaccine
Pfizer vaccine

Global pharma major is sending its medicines worth USD 70 million (over Rs 510 crore), from its distribution centres in the US, Europe and Asia, that have been identified as part of India's COVID-19 treatment protocol, the company's Chairman and CEO Albert Bourla said on Monday.

"We are deeply concerned by the critical COVID-19 situation in India, and our hearts go out to you, your loved ones and all the people of India," he said in a mail sent to India employees that he has shared on his post.

"We are committed to being a partner in India's fight against this disease and are quickly working to mobilize the largest humanitarian relief effort in our company's history," Bourla said.

Right now, colleagues at distribution centres in the US, Europe and Asia are hard at work rushing shipments of Pfizer medicines that the Government of India has identified as part of its COVID-19 treatment protocol, he added.

"We are donating these medicines to help make sure that every COVID-19 patient in every public hospital across the country can have access to the Pfizer medicines they need free of charge," Bourla said.

These medicines, valued at more than USD 70 million, will be made available immediately, and "we will work closely with the government and our NGO partners to get them to where they are needed most," he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, May 03 2021. 13:09 IST